Trials / Withdrawn
WithdrawnNCT02069717
Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)
Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial infarction and are diagnosed with metabolic syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Not applicable-observational study |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2014-02-24
- Last updated
- 2016-10-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02069717. Inclusion in this directory is not an endorsement.